Document:

TLLP EX.10.20 12.31.2014

Exhibit 10.20

QEPM OMNIBUS SIDE AGREEMENT

This QEPM Omnibus Side Agreement (this "Agreement") is dated as of February 11, 2015, by and among Tesoro Logistics GP, LLC, a Delaware limited liability company ("TLGP") and Tesoro Logistics LP, a Delaware limited partnership ("TLLP"). TLGP and TLLP are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

RECITALS:

A.The Parties and certain of their affiliates entered into the First Amended and Restated Omnibus Agreement, dated as of December 2, 2014 (the "A&R Omnibus Agreement"), which governs the provision of certain services by the Parties to QEP Midstream Partners, LP, a Delaware limited partnership, and its subsidiaries (collectively, the "Partnership Group").

B.Pursuant to Section 3.2 of the A&R Omnibus Agreement, the Administrative Fee (as defined in the A&R Omnibus Agreement) for the services provided by the Parties are paid directly to TLGP, regardless of which entity performed services on behalf of the Partnership Group.

C.The Parties desire to enter into this agreement to clarify the apportionment of the Administrative Fee between the Parties for the services rendered by each of them and the determination of the Administrative Fee in certain instances.

NOW, THEREFORE, in consideration of the premises and the mutual promises, representations, warranties, covenants, conditions and agreements contained herein, and for other valuable consideration, the receipt and sufficiency of which are hereby acknowledged,  the Parties, intending to be legally bound by the terms hereof, agree as follows:

ARTICLE I 
DEFINITIONS AND INTERPRETATION

Section 1.1    Definitions. In addition to the terms defined in the introductory paragraph and the recitals of this Agreement, for purposes hereof, the capitalized terms used herein and not otherwise defined shall have the meanings set forth in the A&R Omnibus Agreement.

Section 1.2    Rules of Construction.    Unless expressly provided for elsewhere in this Agreement, this Agreement shall be interpreted in accordance with the rules of construction set forth in Section 1.2 of the A&R Omnibus Agreement.

ARTICLE II

DETERMINATION AND PAYMENT OF 
ADMINISTRATIVE FEE

Section 2.1     Subject to Section 2.2 below, upon each payment of the Administrative Fee to TLGP by the Partnership Group pursuant to Section 3.2(c)(ii) of the A&R Omnibus Agreement, TLGP will promptly thereafter remit a payment  equal to $850,000 to TLLP in

consideration for the services rendered by TLLP on behalf of the Partnership Group (the "TLLP Payment'). No  later than 15 calendar days after the end of each calendar month, TLLP  shall provide TLGP with reasonable documentary support with respect to the amount of the TLLP Payment.

Section 2.2     If the TLLP Payment is either insufficient to reimburse TLLP for, or is in excess of, costs incurred by TLLP in providing services on behalf of the Partnership Group in any period during the term of the A&R Omnibus Agreement, the Parties may adjust the TLLP Payment as mutually agreed for such term (the "Adjusted TLLP Payment'); provided, however, that if such adjustment is necessary, TLLP shall provide TLGP with a revised payment amount and reasonable documentary support thereof in sufficient time for TLGP to timely prepare and submit the invoice or invoices required by Section 3.2(c)(i) of the A&R Omnibus Agreement. The Adjusted TLLP Payment shall remain in effect for the term agreed upon by the Parties, after the expiration of which, the payment will revert to the amount of the TLLP Payment set forth in Section 2.1 above.

ARTICLE III 
MISCELLAEOUS

Section 3.1     Except as  otherwise  provided  herein,  all  costs  and  expenses  (including legal and financial advisory fees and expenses) incurred in connection with, or in anticipation of, this Agreement and the transactions contemplated hereby shall be paid by the Party incurring such expenses.

Section 3.2      This Agreement shall be construed in accordance with and governed by the laws of the State of Texas, without regard to the principles of conflicts of law.

Section 3.3     This Agreement constitutes the entire agreement between the Parties pertaining to the subject matter hereof, and supersedes all  prior agreements, understandings, negotiations and discussions, whether oral or written, of the Parties pertaining to the  subject matter hereof.

Section 3.4     This Agreement may be executed in counterparts, each of which shall be deemed an original instrument, but all such counterparts together shall constitute one agreement. A Party's delivery of an executed counterpart signature page by facsimile (or electronic .pdf format transmission) is as effective as executing and delivering this Agreement in the presence of the other Party. No Party shall be bound until such time as all of the Parties have executed counterparts of this Agreement.

Section 3.5     Except as otherwise contemplated by this Agreement, all covenants and agreements of the Parties contained in this Agreement shall survive from the date hereof and remain in full force and effect in accordance with their applicable terms.

Section 3.6     A failure by any Party to -comply with any of its obligations, agreements or conditions herein contained may be waived by either Party,  as  applicable,  by  an  instrument signed by  such party  and  expressly identified  as a waiver,  but not  in any other manner.    No

2

waiver of, or consent to a change in, any of the provisions of this Agreement shall be deemed or shall constitute a waiver of, or consent to a change in, other provisions hereof (whether or not similar), nor shall such waiver constitute a continuing waiver unless otherwise expressly provided.

Section 3.7     This Agreement may be amended or modified only by an agreement in writing executed by all Parties and expressly identified as an amendment or modification.

Section 3.8     Except as otherwise expressly provided for in this Agreement, no Party shall assign all or any part of this Agreement, nor shall any Party assign or delegate any of its rights or duties hereunder, without the prior written consent of the other Parties (which consent may be withheld for any reason) and any assignment or delegation made without such consent shall be void. Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and assigns.

Section 3.9     Each of the Parties shall cause to be performed all actions, agreements and obligations set forth herein to be performed by any Subsidiary or Affiliate of such Party or by any entity that becomes a Subsidiary or Affiliate of such Party on and after the date hereof.

Section 3.10    Except as otherwise expressly provided in this Agreement, this Agreement is solely for the benefit of the Parties and should not be deemed to confer upon third parties any remedy, claim, liability, reimbursement, cause of action or other right in excess of those existing without reference to this Agreement.

Section 3.11    The invalidity or unenforceability of any term or provision of this Agreement in any situation or jurisdiction shall not affect the validity or enforceability of the other terms or provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction and the remaining terms and provisions shall remain in full force and effect, unless doing so would result in an interpretation of this Agreement that is manifestly unjust.

[Signature Pages Follow]

3

IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the day and year first above written.

TESORO LOGISTICS GP, LLC

By:             /s/ PHILLIP M. ANDERSON         
Name:    Phillip M. Anderson  
Title:    President 

TESORO LOGISTICS LP

By:    Tesoro Logistics GP, LLC, its general partner

By:             /s/ PHILLIP M. ANDERSON        
Name:    Phillip M. Anderson  
Title:    President

Signature Page to Side Agreement- QEPM OmnibusExhibit 10.54

 

CONFIDENTIAL

 

Pursuant to 17 C.F.R §240.24b-2, confidential information (indicated as [***]) has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission.

 

Third Amendment to Distribution Agreement

(TYVASO®)

 

THIS THIRD AMENDMENT TO DISTRIBUTION AGREEMENT  (this “Third Amendment”) is made and effective this 20th  Day of October, 2014 (the “Third Amendment Effective Date”) by and among, United Therapeutics Corporation, a Delaware corporation having offices at 1040 Spring Street, Silver Spring, Maryland (“UT”), Accredo Health Group, Inc., a Delaware corporation having offices at 6272 Lee Vista Boulevard, Orlando FL, 32822 (“Accredo”), CuraScript, Inc., a Delaware corporation having offices at 6272 Lee Vista Boulevard, Orlando FL, 32822 (“SP”) and Priority Healthcare Distribution, Inc., doing business as CuraScript SD Specialty Distribution, a Florida corporation with offices at 255 Technology Park, Lake Mary, Florida, 32746 (“SD”). SP, SD and Accredo are collectively referred to herein as the “Distributor”.

 

WHEREAS, UT and Accredo entered into a Distribution Agreement on August 17, 2009 (as amended from time to time, the “Agreement”) relating to the distribution of Tyvaso® (treprostinil) Inhalation Solution; and

 

WHEREAS, the parties desire to amend the Agreement as provided herein, in order to make the Institutional Starter Kit and Supplemental Refill Kit referenced in Attachment A available for purchase by Distributor.

 

NOW, THEREFORE, in consideration of the mutual agreements and covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows:

 

1.              AMENDMENT.  The Agreement is hereby amended by deleting Attachment A in its entirety, and replacing it with Attachment A to this Amendment.

 

2.              COUNTERPARTS. This Amendment may be executed in any number of counterparts and via facsimile, email or other electronic form of transmission, and each of such counterparts shall for all purposes be deemed original, and all such counterparts shall together constitute one and the same instrument.

 

3.              EFFECT OF AMENDMENT.  Except as specifically amended hereby or by any previous amendments duly executed in accordance with the Agreement, all other terms and conditions of the Agreement remain in full force and effect. To the extent that any of the terms in the underlying agreement are inconsistent with the terms of this Amendment, the terms of this Amendment shall control.

 

[Signature page follows]

 

1

 

IN WITNESS WHEREOF, the parties hereto have caused this Third Amendment to be executed by their duly authorized representatives.

 

	
UNITED THERAPEUTICS
    	
ACCREDO HEALTH GROUP, INC.
    
	
CORPORATION
    	
 
    
	
 
    	
 
    
	
/s/ Jay A. Watson
    	
 
    	
/s/ David A. Norton
    
	
 
    	
 
    	
 
    
	
Name: 
    	
Jay   A. Watson, Pharm.D.
    	
 
    	
Name:   
    	
David   A. Norton
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
Executive   Vice President, Strategic
    	
 
    	
Title:
    	
Senior   Vice President
    
	
 
    	
Operations   and Logistics
    	
 
    	
 
    	
 
    
	
Date:
    	
20/Nov/2014
    	
 
    	
Date:
    	
December 10,   2014
    
	
 
    	
 
    
	
 
    	
 
    
	
CURASCRIPT, INC.
    	
PRIORITY   HEALTHCARE
    
	
 
    	
DISTRIBUTION, INC.
    
	
 
    	
 
    
	
/s/   David A. Norton
    	
 
    	
/s/ Gayle C. Johnston
    
	
 
    	
 
    	
 
    
	
Name: 
    	
David   A. Norton
    	
 
    	
Name:
    	
Gayle C. Johnston
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
Senior   Vice President
    	
 
    	
Title:
    	
President
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
December 10,   2014
    	
 
    	
Date:
    	
12-4-14
    

 

2

 

Attachment A

 

	
Product Name
    	
 
    	
NDC Code
    	
 
    	
Price
    
	
Tyvaso   Patient Starter Kit   (PSK)
    	
 
    	
66302-206-01
    	
 
    	
$
    	
[ *** ]
    
	
Tyvaso   Patient Resupply Kit (RSK)
    	
 
    	
66302-206-02
    	
 
    	
$
    	
[ *** ]
    
	
Tyvaso   Supplemental Refill 4 ct
    	
 
    	
66302-206-03
    	
 
    	
$
    	
[ *** ]
    
	
Tyvaso   Institutional Starter Kit (ISK)
    	
 
    	
66302-206-04
    	
 
    	
$
    	
[ *** ]
    

 

NDC 66302-206-01 Tyvaso Starter Kit includes:

·                  28 ampoules of Tyvaso

·                  2 Sets of Autoclavable Parts

·                  2 Tyvaso Inhalation Devices

·                  2 AC Power Adapters

·                  1 Rechargeable Battery Pack

·                  1 Car Power Cord

·                  1 Leather Carrying Case

·                  32 Medicine Cups

·                  64 Filter Membranes

·                  1 Nose Clip

·                  1 Measuring Cup

·                  1 Safety Box

·                  2 Sets of Safety Plugs

 

NDC 66303-206-02 Tyvaso Re-Supply Kit includes

·                  28 ampoules of Tyvaso

·                  1 Set of Autoclavable Parts

·                  32 Medicine Cups

·                  64 Filter Membranes

 

NDC 66302-206-03 Tyvaso Supplemental Refill includes

·                  4 ampoules of Tyvaso

 

NDC 66302-206-04 Tyvaso Institutional Starter Kit (ISK)

·                  4  ampoules of Tyvaso

·                  2 Sets of Autoclavable Parts

·                  2 Tyvaso Inhalation Devices

·                  2 AC Power Adapters

·                  1 Rechargeable Battery Pack

·                  1 Car Power Cord

·                  1 Leather Carrying Case

·                  32 Medicine Cups

·                  64 Filter Membranes

·                  1 Nose Clip

·                  1 Measuring Cup

·                  1 Safety Box

·                  2 Sets of Safety Plugs

 

3

 

UT shall notify the DISTRIBUTOR in writing of any change (and the amount of the change) in the Price of any respective UT Product during the term of this Agreement in the same time and manner as it notifies other similarly situated distributors.

 

UT shall provide DISTRIBUTOR with a current list of Tyvaso prices to Discounted Entities, including FSS prices, Federal Ceiling Prices, and prices to section 340B entities, and shall promptly notify Distributor of any and all changes in such prices as well as the effective dates of such changes.

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}]]